From LncRNA to metastasis: The MALAT1-EMT axis in cancer progression

Thapa, Riya; Afzal, Obaid; Afzal, Muhammad; Gupta, Gaurav; Bhat, Asif Ahmad; Hassan almalki, Waleed; Kazmi, Imran; Alzarea, Sami I.; Saleem, Shakir; Arora, Poonam; Singh, Sachin Kumar; Dua, Kamal

doi:10.1016/j.prp.2023.154959

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article2

Preprint1

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

References 112 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Noncoding RNAs as therapeutic targets in autophagy-related diabetic cardiomyopathy

Break,

Syed,

Hussein

et al. 2024

Pathology - Research and Practice

View full text Add to dashboard Cite

Noncoding RNAs as therapeutic targets in autophagy-related diabetic cardiomyopathy

Break,

Syed,

Hussein

et al. 2024

Pathology - Research and Practice

View full text Add to dashboard Cite

Exploring the oncogenic and tumor-suppressive roles of Circ-ADAM9 in cancer

Hussain,

Moglad,

Bansal

et al. 2024

Pathology - Research and Practice

View full text Add to dashboard Cite

Dysregulation of lncRNA MALAT1 Contributes to Lung Cancer in African Americans by modulating the tumor immune microenvironment

Li,

Dhilipkannah,

Holden

et al. 2024

Preprint

View full text Add to dashboard Cite

African American (AA) populations present with notably higher incidence and mortality rates from lung cancer in comparison to other racial groups. Here, we elucidate the contribution of long non-coding RNAs (lncRNAs) in the racial disparities and their potential clinical applications in both diagnosis and therapeutic strategies. AA patients had elevated plasma levels of MALAT1 and PVT1 compared with cancer-free smokers. Incorporating these lncRNAs as plasma biomarkers, along with smoking history, achieved 81% accuracy in diagnosis of lung cancer in AA patients. We observed a rise in MALAT1 expression, correlating with increased levels of monocyte chemoattractant protein-1 (MCP-1) and CD68, CD163, CD206, indicative of tumor-associated macrophages in lung tumors of AA patients. Forced MALAT1 expression led to enhanced growth and invasiveness of lung cancer cells, both in vitro and in vivo, accompanied by elevated levels of MCP-1, CD68, CD163, CD206, and KI67. Mechanistically, MALAT1 acted as a competing endogenous RNA to directly interact with miR-206, subsequently affecting MCP-1 expression and macrophage activity, and enhanced the tumorigenesis. Targeting MALAT1 significantly reduced tumor sizes in animal models. Therefore, dysregulated MALAT1 contributes to lung cancer disparities in AAs by modulating the tumor immune microenvironment through its interaction with miR-206, thereby presenting novel diagnostic and therapeutic targets.

show abstract

From LncRNA to metastasis: The MALAT1-EMT axis in cancer progression

Cited by 3 publications

References 112 publications

Noncoding RNAs as therapeutic targets in autophagy-related diabetic cardiomyopathy

Noncoding RNAs as therapeutic targets in autophagy-related diabetic cardiomyopathy

Exploring the oncogenic and tumor-suppressive roles of Circ-ADAM9 in cancer

Dysregulation of lncRNA MALAT1 Contributes to Lung Cancer in African Americans by modulating the tumor immune microenvironment

Contact Info

Product

Resources

About